Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / mortality*
  • Glucosides / therapeutic use*
  • Humans
  • Mortality / trends
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin